Henrik Bindesbøl Mortensen

​Expertise

Experts skills in in patient-oriented translational and clinical research to:

1. Understand the pathogenesis to type 1 diabetes 
   
2. Develop biomarkers for disease prediction, progression and therapeutic response
   
3. Prolong the period with residual beta cell function
   
4. Improve the outcome of diabetes treatment
   
5. Understand and halt the increasing trend of type 1 diabetes.
   

Main research areas

Pathophysiology and pathogenesis of type 1 diabetes with special attention to the period with residual beta cell function in new onset type 1 diabetes.

Identification of new biomarkers for beta cell replication or decay.

Launch of intervention studies with the aim of preserving the residual beta cell function to prolong the period with residual beta cell function or even make it permanent.    

Current research

• Genetic and immunologic markers associated to glycaemic control in children with T1D
  
• The effects of breast milk derived microRNA of type 1 diabetic mothers on disease development and progression in the infant
  
• A longitudinal analysis of beta cell loss during the first 12 month of T1D
  
• Circulating microRNAs as biomarkers for autoimmunity and disease progression in newly diagnosed children with T1D
  
• Association of life conjuncture quality of life, blood glucose control on development of diabetic retinopathy, nephropathy, and neuropathy. Investigation of final hight, weight BMI, blood pressure and which covariates are associated with these outcomes
  
• The influence of New Nordic Diet on trace elements determined at birth on the programming of healthy children
  

Funding

PhD Scholarship Awards: Copenhagen University and Herlev Hospital Research Fund 
EFSD, Novo Nordisk
Capital Region of Denmark’s Research fund for Health Science
INNODIA